Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: A systematic review and economic analysis

Health Technology Assessment

Volumn 8, Issue 28, 2004, Pages

  Dalziel, K ^a   Round, A ^a   Stein, K ^a   Garside, R ^a   Price, A ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CYTARABINE; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; PREDNISOLONE;

ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; BODY WEIGHT DISORDER; BONE MARROW TRANSPLANTATION; BONE PAIN; BRAIN EDEMA; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; CYTOGENETICS; DEATH; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ECONOMIC ASPECT; ECZEMA; EFFUSION; ELECTRONIC MEDICAL RECORD; ERYTHEMA NODOSUM; EYE DISEASE; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; INFECTION; INFESTATION; LARYNX DISORDER; LICHENOID ERUPTION; LIMB PAIN; LIVER NECROSIS; MENTAL DISEASE; METABOLIC DISORDER; MIGRAINE; MUCOSA INFLAMMATION; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NIGHT SWEAT; NUTRITIONAL DISORDER; PERIPHERAL EDEMA; PHARYNX DISEASE; PITYRIASIS ROSEA; PROBABILITY; PROFESSIONAL STANDARDS REVIEW ORGANIZATION; PRURITUS; PUSTULOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; RIGOR; SKIN DISEASE; SMALL VESSEL VASCULITIS; STATISTICAL MODEL; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THORAX DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 4444283314     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
2. Hernandez-Boluda JC, Cervantes F, Alvarez A, Costa D, Montserrat E. Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. Ann Hematol 2001;80:516-20.
3. Talpaz M, Silver RT, Druker B, Goldman DM, Gambacorti-Passerini C, Gnilhot F, et al. Glivec™ (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Basel: Novartis Pharma; 2001. 11-9-0001.
4. Kumar P, Clark M. Clinical medicine. 4th ed. Edinburgh: WB Saunders, 1998; 425-32.
5. Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group. Blood 1998;91:2713-21.
6. Broustet A, Reiffers J, Marit G, Fiere D, Jaubert J, Reynaud J, et al. Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study. Eur J Cancer 1991;27 Suppl 4:S18-21.
7. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84:4064-77.
8. Bolton AE, Gathmann I. A phase III study of ST1571 versus interferon alpha (IFNα) combined with Cytarabine (Ara-C) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP). Basel: Novartis Pharma; 2002.
9. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 1998;91:1810-19.
10. Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, et al. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. Bone Marrow Transplant 2002;29:1-8.
11. Ohnishi K, Minami S, Ueda T, Nishimura M, Tsubaki K, Takemoto Y, et al. Multicentre prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Int J Hematol 2000;72:229-36.
12. Ohnishi K, Ino T, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, et al. Multicentre prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis. Cancer Chemother Pharmacol 2001;48:S59-64.
13. Taylor PA. Northern leukaemia register. Newcastle. 2000.
14. Lamvik J, Brinich L, Dahl I, Sjo M, Nesthus I, Tangen J, et al. Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96 [In Norwegian]. Tidsskr Nor Laegeforen 1999;119:1736-3.
15. Perkins D, Brennan S, Carstairs K, Bailey D, Pantalony D, Poon A, et al. Regional cancer statistics: a report on 1143 diagnostic cases. Cancer Genet Cytogenet 1997;96:64-80.
16. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001;6:233-8.
17. Clarkson BSA. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukaemia and relevance to treatment. Leukemia 1993;7:1683-721.
18. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol 2001;29:543-56.
19. Bose S, Deninger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical bcr abl fusion genes in leukocytes of normal individuals: biological significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-7.
20. Minot G, Buckman T, Isaacs R. Chronic myelogenous leukemia. JAMA 1924;82:1489-94.
21. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998;92:1541-8.
22. Hehlmann R, Heimpel H, Hasford J, Allan N, Burnett A, Shepherd P, et al. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Br J Haematol 2000;110:573-6.
23. Giralt S, Kantarjian H, Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol 1995;32:152-8.
24. Hasford J, Pfirmann M, Hehlmann R, Allan NC, Baccarani M, Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8.
25. Bonifazi F, De Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-81.
26. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German Chronic Myeloid Leukaemia (CML) Study Group. Br J Haematol 1997;97:76-85.
27. Hehlmann R, Hochhaus A, Berger U, Muth A, Kolb HJ, Pfirrmann M, et al. Survival after allogenous bone marrow transplantation in patients with chronic myeloid leukemia (CML) is not influenced by pretransplant interferon alpha therapy. Br J Haematol 1998;102:317.
28. Bonifazi F, De Vivo A, Rosti G, Tiribelli M, Russo D, Trabacchi E, et al. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon. Br J Haematol 2000; 111:587-95.
29. Talpaz M. Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin Hematol 2001;38:22-7.
30. Wisloff FHM. Effect of interferon on the health related quality of life of multiple myeloma patients: results of a Nordic randomised trial comparing melphalan-prednisone to melphalan-prednisone plus alpha interferon. Br J Haematol 1996;94:324-32.
31. Bertero C, Eriksson BE, Ek AC. Explaining different profiles in quality of life experiences in acute and chronic leukemia. Cancer Nurs 1997;20:100-4.
32. Maloisel F, Uettwiller F, Laplace A, Lioure B, Herbrecht R, Mark M, et al. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia. Cancer Genet Cytogenet 1999;113:172-6.
33. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9.
34. Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, et al. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multicenter phase II study. Leuk Res 1997;21:75-80.
35. Baccarani M, Rosti G, De Vivo A, Bonifazi F. Russo D, Martinelli G, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-35.
36. European Agency for the Evaluation of Medicinal Products. Committee for Propriety Medicinal Products European Public Assessment Report: Glivec CPMP/2418/01. London: EMEA. 2001.
37. O'Dwyer ME, Mauro MJ, Aust S, Kuyl J, Paquette R, Sawyers C, et al. Ongoing evaluation of the combination of Imatinib mesylate (Glivec™) with low dose interferon-alpha for the treatment of chronic phase CML. European Hematology Association (EHA) Annual Meeting, Florence, Italy. 6-9 June 2002.
38. O'Brien SG, Vallance SE, Craddock CM. Pegintron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. British Society for Haematology, 42nd Annual Scientific Meeting Brighton, UK, 15-18 April 2002. Br J Haematol 2002;117:3-4.
39. Trabacchi E, Bassi S, Saglio G, Rege-Cambrin G, Bonifazi F, De Vivo A, et al. Pegylated recombinant interferon alpha2b (Pegintron) associated with imatinib mesylate (Glivec) in Ph chronic myeloid leukaemic (CML) in early chronic phase: a phase II study of the ICSG on CML. European Hematology Association (EHA) Annual Meeting, Florence, Italy. 6-9 June 2002.
40. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001;286:895-8.
41. Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-46.
42. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94:1517-36.
43. Mughal TI, Goldman JM. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma. Eur J Cancer 2001;37:561-8.
44. Kumar PCM, Clark M. Clinical medicine. 4th ed. Edinburgh: WB Saunders, 1998.
45. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 200;355:1199-200.
46. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62-6.
47. Tkachuk DC, Westbrook CA, Andreff M, Donlon TA, Cleary ML, Survanaravan K, et al. Detection of bcr-abl fusion in chronic myeloid leukemia by in situ hybridization. Science 1990; 250:559-62.
48. Cross NC. Competitive polymerase chain reaction to estimate the numbers of Bcr-Abl transcripts of chronic myeloid leukemia. Blood 1993;82:1929-36.
49. Baron F, Frere P, Fillet G, Beguin Y. Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica 2001; 86:993-4.
50. Hehlmann R, Willer A, Heimpel H, Hasford J, Kolb HJ, Pralle H, et al. Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. Leukemia 1997;11 (Suppl 3):506-11.
51. Silver RT, Karanas A, Dear KB, Weil M, Brunner K, Haurani F, et al. Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study. Leuk Lymphoma 1992;7:63-8.
52. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987;69:1280-8.
53. Cortes J, Kantadian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996;100:452-5.
54. Sawyers CL. Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia. Semin Hematol 2001;38:S1-42.
55. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
56. Krystal GW. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 2001;4: 16-21.
57. Korycka A, Robak T. The comparison of influence of STI571 used alone or in combination either with 2-chlorodeoxyadenosine or fludarabine on the normal and chronic myelogenous leukemia progenitor cells in vitro. European Hematology Association (EHA) Annual Meeting, Florence, Italy. 6-9 June 2002.
58. Druker BJ. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomised study. America Society of Clinical Oncology Annual Meeting, Orlando, FL, USA, 18-21 May 2002; Abstract No. 1.
59. Schad M, Toplay J, Zeller W, Fruehauf S. Imatinib in combination with 17-allylamino-17-dexethoxygeldanamycin (17-AAG) for treatment of chronic myelogenous leukemia. European Hematology Association (EHA) Annual Meeting, Florence, Italy. 6-9 June 2002; Abstract No. 1005.
60. Fruehauf S, Toplay J, Schad M, Ho AD, Zeller WJ. Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. International Society for Experimental Hematology Annual Meeting, Montreal, Canada, 5-9 July 2002; Abstract No. 224.
61. Drummond M, McGuire A. Economic evaluation in health care. Oxford: Oxford University Press; 2001.
62. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002;8:2177-87.
63. Novartis Pharmaceuticals UK. Appraisal of Glivec for 1st line treatment of chronic myeloid leukaemia. Camberley: Novartis Pharma AG; 2003.
64. Shepherd PC, Richards SM, Allan NC. Progress with interferon in CML - results of the MRC UK CML III study. Bone Marrow Transplant 1996;17 Suppl 3:S15-18.
65. Ohnishi K, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, et al. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. Leuk Res 1998;22: 779-86.
66. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616-20.
67. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared to interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 2003; 348:994-1004.
68. Clark TJ, Khan KS, Foon R, Pattison H, Bryan S, Gupta JK. Quality of life instruments in studies of menorrhagia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2002;104:96-104.
69. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002; 347:446.
70. Drummond A, Micallef-Eynaud P, Douglas WS, Murphey A, Hay I, Holyoake TL, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003;120:911-13.
71. Milojkovic D, Short KJ. Dose limiting dermatological toxicity secondary to imatinib mesylate (STI-571) in chronic myeloid leukaemia (CML). British Society for Haematology, 42nd Annual Scientific Meeting, Brighton, UK, 15-18 April 2002. Br J Haematol 117:16-7.
72. Ebnoether M, Stentoft J, Ford J, Buhl L, Gratwohl A. Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002;359:1751-2.
73. Barton JC, Jones SC, Lamberth WC, Reymann MT, Scott VC. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 2002;71:139-40.
74. Vidal D, Puig L, Sureda A, Alomar A. Sti571-induced Stevens-Johnson Syndrome. Br J Haematol 2002;119:274-5.
75. Lim DS, Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 2002;205:169-71.
76. Lim D, Muir J. Lichenoid eruption to STI 571. Am J Hematol 2002;70:179.
77. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantadian HM, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002;95:881-7.
78. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology 2002;205:172-3.
79. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001;345:618-9.
80. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002;16:2160-1.
81. Hehlmann R, Heimpel H, Kolb HJ, Heinze B, Hochhaus A, Griesshammer M, et al. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 1994;11 Suppl 1:159-68.
82. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Monitoring treatment and survival in chronic myeloid leukemia.J Clin Oncol 1999;17:1858-68.
83. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997;15:2673-82.
84. Messori A. A cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol 1998;9:389-96.
85. Gold MR. Siegel JE. Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
86. Freund M, Grote-Metke AF, Nowak RF, Otremba BF, Wormann BF, Koch OF, et al. Combination of chemotherapy and interferon alfa-wb in the treatment of chronic myelogenous leukemia. Semin Hematol 1993;30:11-3.
87. Warren E, Gordois A, Ward S, Scuffham P. The clinical and cost effectiveness of Imatinib (Glivec, STI571) for chronic myeloid leukaemia (CML). American Society of Clinical Oncology Meeting 1094, Orlando, FL, USA, 18-21 May 2002.
88. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996; 125:541-8.
89. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph + chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 1992;77:204-14.
90. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myclogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-84.
91. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in CML after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995;122:254-61.
92. Tarumoto T. Characterization of an STI571-resistant, BCR/ABL-positive cell line: a possible mechanism of resistance. 30th Annual Meeting of the International Society for Experimental Hematology, Tokyo, Japan, 25-28 August 2001. Exp Hematol 39.
93. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, et al. Bcr-Abl kinase inhibition as the basis of therapy for CML. 29th Annual Meeting of the International Society for Experimental Hematology, Tampa, FL, USA, 8-11 July 2000. Exp Hematol 130.
94. Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997;127:1080-8.
95. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-16.
96. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-7.
97. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994;330:820-5.
98. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985;66:1352-7.
99. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.
100. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
101. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993;81:543-50.
102. Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998;92:4047-52.
103. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000;17:461-77.
104. Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for CML in chronic phase -2003. Semin Hematol (in press).
105. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96: 1070-9.
106. Weisberg E. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
107. + leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 2000; 92:1641-50.
108. Gambacorti-Passerini C, Barni R, Marchesi E, Verga M, Rossi F. Rossi F, et al. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol 2001;112:972-4.